A Revolutionary Approach to Investing in Healthcare Innovation and Biotech
As the world experiences a shift towards alternative assets among retail investors, one industry remains notoriously difficult to navigate: healthcare innovation and biotech. However, one startup is changing the game. Bioverge, a pioneering fintech platform, is making waves by democratizing investments in curated healthcare and technology startups. The company has raised over $8 million and boasts an impressive portfolio of 37 companies.
Bioverge’s mission is to break down the barriers associated with investing in the healthcare sector. Using an artificial intelligence-driven diligence process, Bioverge offers individuals, family offices, and institutions the opportunity to invest in groundbreaking healthcare solutions. Investors can choose between deal-by-deal investments, thematic funds centered around areas like longevity and digital health, or Bioverge Access Funds which offer diversification across 15+ startups.
The company’s business model caters to a diverse range of investors and ensures a democratized approach to healthcare investments. The syndication model aggregates investors into a Special Purpose Vehicle (SPV) that invests directly in companies.
Bioverge has an impressive track record, with a realized net internal rate of return (IRR) of 24.7% and a multiple on invested capital (MOIC) of 2.3x. They have successfully co-invested with well-known venture capital firms such as Andreessen Horowitz, Sequoia, and Khosla.
With a vision to tackle healthcare’s most pressing challenges, Bioverge handpicks startups with world-changing potential and lucrative financial returns. The company’s leadership team, with expertise in life sciences, technology commercialization, and venture capital, is dedicated to making investment decisions that have a positive impact on society.
Bioverge has received significant backing from prominent angel investors and recently raised over $2.3 million from a network of 500+ investors. This support includes notable figures like Sonia Arrison at 100 Plus Capital and members from premier angel groups in Silicon Valley.
For those interested in being part of this transformative journey, Bioverge offers investors the opportunity to invest in the future of healthcare.
